Immune Globulin Intravenous, human-ifas (Octapharma)

N/A

Report date: 2023/07/26 15:35:58

Base Information

Drug NameImmune Globulin Intravenous, human-ifas (Octapharma)
Drug Alias NameIGIV (Octapharma)IVIG (Octapharma)Immune Globulin Intravenous (Human)-ifasPanzygaNewGam
ClassificationBiologics > Blood components
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Psychotic Disorders +[29] 
Global Approved IndicationsImmunologic Deficiency SyndromesPurpura, Thrombocytopenic, Idiopathic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/08/02
Country/TerritoryCzechiaBulgariaCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesOctapharma
China Registration ClassN/A

Develop Information

Active CompaniesOctapharmaUniversity Of Cambridge
Inactive CompaniesMaastricht University Medical CenterGammacanHormozgan University Of Medical Sciences +[11] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Psychotic DisordersImmunologic Deficiency Syndromes +[10] 
Inactive IndicationsRejection of lung transplantationScleroderma, SystemicPrimary Immunodeficiency Diseases +[19] 

Other Information

ATC CodeJ06BA02
Related LinksN/A